There are an estimated 5,500,000 people in the U.S. who have Alzheimers disease, and we have developed an innovative treatment that addresses the cause of the disease rather than the symptoms. By this treatment strategy, we are addressing a significant unmet medical need and opportunity. Our patented technology was developed over a decade with the support of $4.5 million in grants and has successfully improved memory in mice in our proof of concept trials. Our team is comprised of top experts in their fields, including our founder who trained at Yale School of Medicine for about a decade prior to founding this company.
Recombinant Technologies is developing a revolutionary treatment for Alzheimer's Disease. By designing an injection of a molecule treatment to reduce the plaque buildup that causes dementia, we have successfully improved memory in mice and are ready to move toward human trials.